PGEN — PRECIGEN, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1356090 ·
Last close
$4.29
Market Cap
$1.54B
52W High
$8.98
52W Low
$3.04
ADV30
6,525,046
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 74,148,000 | 67,640,000 | 38,650,000 | 35,766,000 | 212,102,000 | 14,959,000 | 128,308,000 |
| Jun 2026 | 54,978,000 | 52,173,000 | 22,642,000 | 20,071,000 | 170,296,000 | 16,329,000 | 126,720,000 |
| Mar 2026 | 23,252,000 | 20,693,000 | -5,994,000 | -7,929,000 | 138,627,000 | 7,480,000 | 118,392,000 |
| Dec 2025 | 4,565,000 | 2,969,000 | -21,666,000 | -23,503,000 | 155,505,000 | 30,234,000 | 134,594,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-73,213,000
Investing CF
$73,549,000
Financing CF
$295,000
CapEx
$-1,103,000
Dividends Paid
—
Buybacks
$-537,000
EPS Diluted TTM
$-0.95
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,293,440,000
Inventory
$22,915,000
Receivables
$96,619,000
ST Investments
$31,112,000
EBIT TTM
$36,426,000
Pretax Income TTM
$24,605,000
Interest Exp TTM
$11,821,000
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$156,943,008
EBITDA
$38,080,000
Free Cash Flow
$-87,127,128
Enterprise Value
$1,655,254,400
Total Cash
$46,071,000
Total Debt
$98,607,000
Shares Out
358,549,980
Trailing EPS
$0.11
Book Value
$0.23
ROE
38.8%
ROA
11.0%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 9,684,000 | -106,600,000 | -250,642,000 | 155,505,000 | 134,594,000 | 20,911,000 | -87,831,000 |
| Dec 2024 | 3,925,000 | -94,705,000 | -126,235,000 | 145,266,000 | 106,753,000 | 38,513,000 | -68,173,000 |
| Dec 2023 | 6,225,000 | -88,923,000 | -95,904,000 | 151,043,000 | 32,545,000 | 118,498,000 | -66,930,000 |
| Dec 2022 | 26,909,000 | -74,606,000 | 28,317,000 | 215,977,000 | 89,718,000 | 126,259,000 | -65,045,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
$-157,705,000
OpCashFlow TTM
—
Assets (Latest)
$170,296,000
Forward EPS
$-0.22
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $5.00 · spot: $4.27 · call volume: 371 · put volume: 39
Expected Move to 2026-12-18:
±$0.90
(21.08%) —
implied range
$3.37 –
$5.17
· ATM straddle on $4.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ADRX | ADARx Pharmaceuticals, Inc. | $1.53B | $13.82 | — |
| NRIX | Nurix Therapeutics, Inc. | $1.56B | $14.24 | — |
| SRPT | Sarepta Therapeutics, Inc. | $1.58B | $14.77 | — |
| KLRA | Kailera Therapeutics, Inc. | $1.58B | $12.20 | — |
| ANIP | ANI PHARMACEUTICALS INC | $1.59B | $69.99 | — |
News headlines (Yahoo Finance, 1h cache)
Precigen Posts Strong Q3: PAPZIMEOS Net Revenue Rose 37%; Positive Cash Flow Achieved Ahead of Schedule
2026-11-10 11:30 · Yahoo
What Makes Precigen (PGEN) a New Buy Stock
2026-11-09 16:00 · Yahoo
PGEN Q3 Earnings Call Highlights Launch Momentum and Competition
2026-11-09 14:00 · Yahoo
Precigen (PGEN) Stock Looks Fully Priced On Current Earnings
2026-11-06 17:20 · Yahoo
Precigen (PGEN) Q3 2026 Earnings Call Transcript
2026-11-05 17:20 · Yahoo
Citizens Raises Papzimeos Sales Forecast After Precigen’s Q3 Topline Beat – Sees 142% Upside Potential In PGEN Stock
2026-11-05 11:55 · Yahoo
Precigen Inc (PGEN) Q3 2026 Earnings Call Highlights: Triple-Digit Revenue Surge, First ...
2026-11-05 05:18 · Yahoo
What Precigen (PGEN) Said on Its Q3 Earnings Call
2026-11-05 05:14 · Yahoo
Precigen, Inc. (PGEN) Q3 Earnings and Revenues Miss Estimates
2026-11-04 21:50 · Yahoo
Precigen Reports Third Quarter 2026 Results Highlighted by Strong Sequential PAPZIMEOS Revenue Growth and Positive Cash Flow Ahead of Guidance
2026-11-04 21:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.